Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 2Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1CNS 1Breast 1

Conditions

Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 62Cyclophosphamide 59Radiotherapy 47Doxorubicin 36Filgrastim 26Irinotecan 24Radiation 23Gemcitabine 23fludarabine 22Magnetic Resonance Spectroscopy 20Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Microarray Analysis × Sarcoma × Clear all
NCT00387400 2023-08-04

Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Canadian Cancer Trials Group

Phase 1 Completed
32 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡